Akkermansia muciniphila akk11 having functions of regulating blood glucose and blood fat, and use thereof

Abstract

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

Description

Muciniphilic Akkermansia Akk11 with blood glucose and blood lipid regulating effects and application thereof TECHNICAL FIELD

[0001] The present application belongs to the technical field of microbial culture, and relates to muciniphilic Akkermansia Akk11 with blood glucose and blood lipid regulating effects and application thereof. BACKGROUND

[0002] Akkermansia muciniphila (Akk) is a strict anaerobe that is commonly colonized in the intestinal tract of humans and other animals, and is negatively correlated with metabolic disorder diseases such as metabolic endotoxemia, obesity insulin resistance and glucose tolerance. Akkermansia muciniphila uses mucin as the only source of carbon and nitrogen elements, controls the basic regulation system of glucose and energy metabolism, can not only protect the integrity of intestinal epithelial cells and mucus layer to play a metabolic protection role, but also can play an anti-inflammatory role through regulatory T cells, endocannabinoid system and non-classical Toll-like receptors in the process of inflammatory reaction.

[0003] Obesity is a disease caused by metabolic problems. In the traditional sense, obesity is defined as the accumulation of visceral and subcutaneous fat and weight gain, which can damage health. Akkermansia muciniphila is colonized in the intestinal tract of humans at different stages of growth. In infancy, Akkermansia muciniphila can be used as a marker of the growth status and diversity of intestinal flora. From early life to adulthood, the number of Akkermansia muciniphila increases significantly, and the detection abundance of Akkermansia muciniphila decreases significantly when suffering from obesity and diabetes.

[0004] Probiotics are defined as "live microorganisms" that have a health impact on the host when ingested in sufficient amounts. When obesity is caused by excessive food energy intake and energy balance problems caused by metabolism, the types and numbers of microorganisms in the intestinal tract of the host will change, thereby making probiotics a potential target. Probiotics can improve lipid metabolism disorders, inflammation, oxidative stress and intestinal microecological disorders caused by high-fat diet, and prevent, improve or treat obesity problems by improving the abundance of intestinal flora. Therefore, how to provide a high-efficiency probiotic-containing microbial preparation that can be used to improve the symptoms of metabolic obesity has become a technical problem to be solved.

[0005] SUMMARY

[0006] The present application provides muciniphilic Akkermansia Akk11 with blood glucose and blood lipid regulating effects and application thereof, and specifically provides muciniphilic Akkermansia Akk11 with blood glucose and blood lipid regulating effects and application thereof in the preparation of products with the effects of preventing, improving or treating obesity, hyperlipidemia and hyperglycemia.

[0007] In a first aspect, the present application provides an Akkermansia muciniphila Akk11 having the function of regulating blood glucose and blood lipid, which is named Akkermansia muciniphila Akk11, has a preservation number of CCTCC NO: M 2024119, and was preserved on January 15, 2024.

[0008] The present application isolates and preserves a new Akkermansia muciniphila Akk11 having the function of regulating blood glucose and blood lipid from a healthy infant fecal sample, which is named Akkermansia muciniphila Akk11 strain, can regulate blood glucose and blood lipid levels, and significantly improve symptoms such as metabolic obesity. Specifically, (1) the ability to decompose and utilize glucose is significantly improved, and the disorder of sugar metabolism is improved; (2) total cholesterol, triglycerides, and low-density lipoprotein cholesterol and other indicators are significantly reduced; (3) the inflammatory response of the gastrointestinal tract caused by metabolic obesity and the like is effectively regulated, and the inflammatory factors are significantly improved. Therefore, the Akkermansia muciniphila Akk11 strain can be used to prepare products having the functions of preventing, improving, or treating obesity, hyperlipidemia, and hyperglycemia.

[0009] In addition, Akkermansia muciniphila is a probiotic, so the Akkermansia muciniphila AK11 screened in the present application has high safety when used in the preparation of related efficacy products; and it will not produce drug resistance, improve the adverse reactions such as endocrine disorders and nausea caused by the use of antibiotics in conventional obese patients, and can be used in products for long-term prevention, improvement, or treatment of metabolic obesity.

[0010] In a second aspect, the present application provides a culture of the Akkermansia muciniphila Akk11 having the function of regulating blood glucose and blood lipid according to the first aspect, which is prepared by inoculating the Akkermansia muciniphila Akk11 strain into a culture medium and culturing at 35-38℃ for 18-22h.

[0011] The above-mentioned "35-38℃" may be, for example, 35℃, 35.5℃, 36℃, 36.5℃, 37℃, 37.5℃, or 38℃, and other specific point values within the numerical range can be selected, which will not be repeated here.

[0012] The "18-22h" can be, for example, 18h, 18.5h, 19h, 19.5h, 20h, 20.5h, 21h, 21.5h, 22h, and other specific point values in the numerical range can be selected, which will not be repeated here.

[0013] In a third aspect, the present application provides a probiotic agent with the function of regulating blood sugar and blood lipid, wherein the strain in the probiotic agent with the function of regulating blood sugar and blood lipid comprises the Akkermansia muciniphila Akk11 strain of the first aspect.

[0014] Preferably, in the probiotic agent, the viable count of the Akkermansia muciniphila Akk11 strain is not less than 1×10 10 CFU / mL or 1×10 10 CFU / g, for example, 1×10 10 CFU / mL (CFU / g), 2×10 10 CFU / mL (CFU / g), 5×10 10 CFU / mL (CFU / g), 8×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), 5×10 11 CFU / mL (CFU / g), or 1×10 12 CFU / mL (CFU / g), and other specific point values in the numerical range can be selected, which will not be repeated here.

[0015] Preferably, the strain in the probiotic agent with the function of regulating blood sugar and blood lipid further comprises Bifidobacterium longum BL21, the taxonomic name of which is Bifidobacterium longum, the accession number is CGMCC No. 10452, and the preservation date is January 27, 2015.

[0016] The present application also creatively finds that the Akkermansia muciniphila Akk11 strain can be compounded with the Bifidobacterium longum BL21 strain to improve obesity, and has a significantly superior effect to single bacterial agent or other compounding methods, which indicates that the Akk11 strain and the BL21 strain have a synergistic effect in improving the ability of glycolysis, improving sugar metabolism disorder, reducing total cholesterol, triglyceride, and low-density lipoprotein cholesterol, and effectively regulating the gastrointestinal inflammation caused by metabolic obesity.

[0017] Preferably, the ratio of viable cell number of the Akkermansia muciniphila Akk11 strain and the Bifidobacterium longum BL21 strain is (1-10):(1-10); wherein "1-10" may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and other specific point values within the numerical range may be selected, which will not be repeated here.

[0018] Preferably, the dosage form of the probiotic agent comprises a freeze-dried powder, a capsule, a tablet, or a granule.

[0019] Preferably, the probiotic agent further comprises a protective agent and / or a functional aid.

[0020] Preferably, the protective agent comprises any one or a combination of at least two of skimmed milk, gelatin, dextrin, acacia gum, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol, or xylitol.

[0021] Preferably, the functional aid comprises any one or a combination of at least two of maltodextrin, fructooligosaccharide, galactooligosaccharide, xylooligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, grifola frondosa polysaccharide, stachyose, polydextrose, alpha-lactalbumin, or lactoferrin.

[0022] In a fourth aspect, the present application provides use of the Akkermansia muciniphila Akk11 strain having the effect of regulating blood glucose and blood lipid as described in the first aspect, or the culture as described in the second aspect, or the probiotic agent as described in the third aspect, in the preparation of a product having the effect of preventing, improving, or treating obesity, hyperlipidemia, hyperglycemia.

[0023] Preferably, the product further comprises an excipient.

[0024] Preferably, the excipient comprises any one or a combination of at least two of a diluent, an excipient, a binder, a wetting agent, a disintegrant, an emulsifier, a co-solvent, a solubilizer, an osmotic pressure regulator, a coating material, a coloring agent, a pH regulator, or a buffer.

[0025] The classification name of the Akk11 strain involved in the present application is Akkermansia muciniphila Akk11, which is preserved in the China Center for Type Culture Collection, with the preservation number CCTCC NO: M 2024119, the preservation date January 15, 2024, and the preservation address Wuhan, China. Wuhan University.

[0026] The classification name of the BL21 strain involved in the present application is Bifidobacterium longum, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.10452, the preservation date is January 27, 2015, and the preservation address is No.3, Beichen West Road, Haidian District, Beijing.

[0027] Compared with the prior art, the present application has the following beneficial effects:

[0028] A new Akkermansia muciniphila strain with the function of regulating blood glucose and blood lipid is separated and preserved in the present application, which is named Akkermansia muciniphila Akk11 strain. The strain can regulate blood glucose and blood lipid levels and significantly improve symptoms such as metabolic obesity. Specifically, (1) the decomposition and utilization ability of glucose is significantly improved, and the sugar metabolism disorder is improved; (2) the total cholesterol, triglyceride and low-density lipoprotein cholesterol and other indicators are significantly reduced; (3) the gastrointestinal inflammation caused by metabolic obesity and other factors is effectively regulated, and the inflammatory factors are obviously improved. Therefore, the Akkermansia muciniphila Akk11 strain can be used to prepare products with the functions of preventing, improving or treating obesity, hyperlipidemia and hyperglycemia. BRIEF DESCRIPTION OF DRAWINGS

[0029] Fig. 1 is a result graph of oral glucose tolerance of mice in each group over time.

[0030] Fig. 2 is a total cholesterol result graph of serum of mice in each group.

[0031] Fig. 3 is a triglyceride result graph of serum of mice in each group.

[0032] Fig. 4 is a high-density lipoprotein cholesterol result graph of serum of mice in each group.

[0033] Fig. 5 is a low-density lipoprotein cholesterol result graph of serum of mice in each group.

[0034] Fig. 6 is an IL-2 result graph of pancreatic cell inflammatory factors of mice in each group.

[0035] Fig. 7 is an IL-6 result graph of pancreatic cell inflammatory factors of mice in each group.

[0036] Fig. 8 is an IL-10 result graph of pancreatic cell inflammatory factors of mice in each group. DETAILED DESCRIPTION

[0037] The technical solutions of the present application are further illustrated by specific embodiments. Those skilled in the art should understand that the embodiments are only used to help understand the present application and should not be regarded as specific limitations on the present application.

[0038] The Akk11 strain involved in the following examples is named Akkermansia muciniphila Akk11, with the accession number CCTCC NO: M 2024119.

[0039] The BL21 strain involved in the following examples is named Bifidobacterium longum, with the accession number CGMCC No. 10452.

[0040] Bifidobacterium longum subsp. longum strain BNCC371780.

[0041] The common feed involved in the following examples is purchased from Shanghai Slike Company; the high-fat high-sugar feed is purchased from Beijing Botaihongda Biological Technology Co., Ltd.; the Tris-HCl buffer is purchased from AMRESCO Company, with the model number BS157-500 g; and the skimmed milk is purchased from Hengtian Nature Group, with the specification of fat ≤1.0% and protein ≥32.9%.

[0042] The MRS medium (g / L) involved in the following examples is as follows: 10 g / L of proteose peptone, 10 g / L of beef extract, 15 g / L of glucose, 15 g / L of lactose, 5 g / L of yeast powder, 2 g / L of diammonium hydrogen citrate, 2.6 g / L of K2PO4·3H2O, 0.1 g / L of MgSO4·7H2O, 0.05 g / L of MnSO4, 1 mL / L of polysorbate 80, and 0.5 g / L of cysteine amino acid salt.

[0043] The bacterial suspension involved in the following examples is prepared as follows: the Akk11 strain, the BL21 strain, and the BNCC371780 strain are inoculated into skimmed milk respectively, activated at 37°C for 18 h, to obtain an activation liquid; the activation liquid is inoculated into the MRS medium at an inoculation amount of 4% (v / v), and cultured at 37°C for 20 h, to obtain a bacterial liquid; the bacterial liquid is centrifuged at 8000 g for 10 min, and the supernatant is filtered through a 0.22 μm sterile filter membrane, to obtain a supernatant; and the bacterial body is resuspended using PBS.

[0044] Example 1

[0045] In this example, an Akkermansia muciniphila strain having the function of regulating blood glucose and blood lipid is isolated and screened, and the steps are as follows:

[0046] (1) Selecting the isolated from healthy infant stool samples, using a mass concentration of 0.9% physiological saline for 10 times gradient dilution, dilution 3 times, coated on solid medium, after 48h culture at 38℃, pick out different morphology of colonies on the surface of modified MRS solid medium streak purification, pick single colony at 37℃ using liquid medium to expand culture, and then using a mass concentration of 35% glycerol for preservation.

[0047] (2) The physiological and biochemical characteristics of the Akkermansia muciniphila in the embodiment are shown in Table 1:

[0048] Table 1

[0049] Example 2

[0050] In this embodiment, the strain screened in Example 1 is subjected to morphological identification and 16S rRNA molecular biology identification, and the steps are as follows:

[0051] (1) Morphological identification:

[0052] The strain is inoculated in MRS solid medium, and after 48h culture at 38℃, it is observed under a microscope. After smearing and Gram staining, it is observed under a microscope that the Gram staining is negative, the strain morphology is non-motile, non-spore-producing, and rod-shaped.

[0053] (2) 16S rRNA molecular biology identification:

[0054] The strain preserved at-80℃ is taken out, inoculated in a centrifuge tube containing 20mL MRS liquid medium at a ratio of 2%, and after 18h culture at 38℃, centrifuged at 8000rpm for 10min, the supernatant is removed, and the bacterial body is collected. The genome of the strain is extracted, bacterial universal primers are added for PCR amplification, and the amplification product is sent to Shanghai Sangon Biological Engineering Co., Ltd. for sequencing identification. The 16S rDNA sequence of the strain is shown as SEQ ID No: 1. The sequence obtained by sequencing is subjected to nucleic acid sequence alignment in GeneBank, and the result shows that the strain is Akkermansia muciniphila.

[0055] SEQ ID No:1:

[0056] Based on the results of 16S rRNA molecular biology identification and morphological identification of Example 2, it is confirmed that the strain belongs to Akkermansia muciniphila, and is named as Akkermansia muciniphila Akk11 strain.

[0057] Test Example 1

[0058] This test example tests the effect of Akk11 strain on slowing down weight gain, and the specific steps are as follows:

[0059] (1) Test animals: 42 6-week-old C57BL / 6 male mice (25 g) were adaptively fed in an animal room (room temperature: 25℃, humidity: 50%, illumination 10 h) for one week (free diet and drinking water) with ordinary feed.

[0060] (2) Grouping: After adaptive feeding, the mice were randomly divided into 7 groups: ordinary-control group, ordinary-experimental group, high-fat-Akk11 group, high-fat-BL21 group, high-fat-Akk11+BL21 combined group, high-fat-Akk11+BNCC371780 combined group, high-fat-control group, 6 mice / group.

[0061] (3) Intervention method:

[0062] (3.1) Ordinary feed group

[0063] Control group: fed with ordinary feed for 30 days, and gavaged with 0.5 mL of PBS buffer once a day for 30 consecutive days;

[0064] Experimental group: fed with ordinary feed for 30 days, and gavaged with 0.5 mL of Akk11 bacterial suspension (concentration 2×10 9 CFU / mL) once a day for 30 consecutive days.

[0065] (3.2) High-fat high-sugar feed group

[0066] Fed with high-fat high-sugar feed, and gavaged with the following any one liquid once a day for 30 consecutive days, thereby forming different experimental groups: 1) Akk11 bacterial suspension 0.5 mL (concentration 2×10 9 CFU / mL); 2) BL21 bacterial suspension 0.5 mL (concentration 2×10 9 CFU / mL); 3) Akk11+BL21 combined bacterial suspension 0.5 mL (total concentration 2×10 9 CFU / mL, ratio of viable bacteria 1:1); 4) Akk11+BNCC371780 combined bacterial suspension 0.5 mL (total concentration 2×10 9 CFU / mL, ratio of viable bacteria 1:1); 5) Control group: PBS buffer 0.5 mL;

[0067] The mice in all groups were allowed to freely eat feed and drink water, and were raised in an animal room (room temperature: 25°C, humidity: 50%, illumination 10 h) for 30 consecutive days. The weight of each mouse in each group was measured at the end of the 30th day, and the average weight gain rate of each group was calculated. The regulatory effect of the bacterial agent on obesity in mice was evaluated according to the weight gain rate. The weight gain rate (%) = (weight of each mouse in each group at the end of the experiment on the 30th day - initial weight before the experiment) / initial weight before the experiment x 100%, and the average weight gain rate (%) = the sum of the weight gain rate of each mouse in each group / the number of mice in each group. The results are shown in Table 2.

[0068] Table 2

[0069] As shown in Table 2, both Akk11 and BL21 bacterial suspensions can slow down the weight gain rate of obese mice, and the slowing effect of the Akk11 bacterial suspension is the best. The weight gain rate of the mice shows a significant downward trend, which is close to that of the ordinary control group of mice. In addition, it is unexpectedly found that the combination of Akk11 and BL21 bacteria has a better slowing effect on the weight gain rate of obese mice, and the weight gain rate of the mice is lower.

[0070] Test Example 2

[0071] This test example tests the ability of the Akk11 strain to decompose and utilize glucose. The specific steps are as follows:

[0072] The grouping and experimental operation are the same as in Test Example 1. After the experiment ended on the 30th day, the oral glucose tolerance (OGTT) of the mice was determined after fasting for 6 h. The mice were orally fed with 1.5 mg / kg of glucose according to their weight. The blood was drawn from the tail of the mice at 0 min, 15 min, 30 min, 60 min and 120 min. The blood glucose was measured using a blood glucose meter, and the curve of oral glucose tolerance over time was plotted, as shown in FIG. 1.

[0073] The results show that the glucose tolerance of the high-fat-control group is higher than that of the normal-control group and the normal-experiment group, proving that the mice fed with high-fat and high-sugar feed have a disorder in the body's regulation of glucose metabolism. After injection of 1.5 mg / kg of glucose, the serum glucose level shows a sharp rise in the first 15 min, and then starts to decline. The oral glucose level between 15-120 min shows a downward trend, but the decline is relatively slow, indicating that the mice fed with high-fat and high-sugar feed have weak ability to decompose and utilize glucose. The Akk11 and BL21 bacterial suspensions can improve the disorder of glucose metabolism in obese mice, and the glucose tolerance values of the mice in each time period are significantly reduced, and the decline rate of the oral glucose level between 15-120 min is significantly improved. Among them, the improvement effect of the Akk11 bacterial suspension is the best. In addition, when the Akk11 and BL21 bacteria are used together, the ability to decompose and utilize glucose in the mice can be further improved, and the ability to improve the disorder of glucose metabolism in obese mice is the best.

[0074] Test Example 3

[0075] This test example tests the ability of the Akk11 strain to regulate blood lipids, and the specific steps are as follows:

[0076] The grouping and experimental operation are the same as in Test Example 1. After the experiment ended on the 30th day, the tail vein blood of the mice was taken, centrifuged at 2000 rpm for 10 min, and the serum was taken. The content of total cholesterol (TC), triglyceride (TAG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) in the serum of each group of mice was detected using a full-automatic biochemical analyzer, and the results are shown in Figures 2-5.

[0077] As can be seen from Figures 2-5, the Akk11 and BL21 bacterial suspensions can reduce the total cholesterol, triglyceride, and low-density lipoprotein of the mice, all of which are lower than those of the high-fat-control group, while the high-density lipoprotein is higher than that of the high-fat-control group. The effect of the Akk11 bacterial suspension is better than that of the BL21 bacterial suspension, and each index tends to be close to that of the normal-control group. In addition, it is unexpectedly found that when the Akk11 and BL21 bacteria are used together, the effect of reducing total cholesterol, triglyceride, and low-density lipoprotein cholesterol and improving the symptoms of blood lipid metabolism disorder in mice is better.

[0078] Test Example 4

[0079] This test example tests the ability of the Akk11 strain to improve inflammatory response, and the specific steps are as follows:

[0080] Grouping and experimental operation are the same as in Test Example 1. After the experiment ended on the 30th day, the mice were dissected, the pancreas tissue was removed, and the pancreas tissue was homogenized using Tris-HCl buffer (pH = 7.4). The homogenate was centrifuged at 1800g at 4°C for 10 min, and the supernatant was collected to analyze the protein concentration and cytokines. The protein concentration was measured using the Coomassie blue staining method; the levels of cytokines interleukin-2 (IL-2), interleukin-6 (IL-6), and interleukin-10 (IL-10) were determined using the ELISA method (Mouse Cytokine Kit, Wuhan Pure Biotechnology), and the results are shown in Figures 6-8.

[0081] As can be seen from Figures 6-8, the values of interleukin-2 and interleukin-6 in the high-fat-control group of mice fed with high-sugar high-fat feed were significantly higher than those in the ordinary-control group fed with ordinary feed, and the value of interleukin-10 was significantly lower than that in the ordinary-control group, indicating that the gastrointestinal inflammation of obese mice fed with high-sugar high-fat feed was more severe than that in the ordinary-control group.

[0082] However, both Akk11 and BL21 bacterial suspensions can reduce the levels of interleukin-2 and interleukin-6 and increase the level of interleukin-10, indicating that the probiotic bacterial suspension can effectively regulate the gastrointestinal inflammatory response of obese mice and significantly improve the levels of inflammatory factors, and the regulation effect of the Akk11 bacterial suspension is the best. In addition, the combination of Akk11 and BL21 bacteria has a better effect on improving the levels of interleukin-2, interleukin-6, and interleukin-10.

[0083] In summary, a new Akkermansia muciniphila strain with the function of regulating blood glucose and blood lipid is isolated and preserved in the present application, which is named Akkermansia muciniphila Akk11. The strain can significantly improve the high weight gain rate, blood lipid metabolism disorder, and gastrointestinal inflammatory response of obese mice, indicating that the Akkermansia muciniphila Akk11 described in the present application is very effective in regulating the symptoms related to metabolism in mice. Therefore, the Akkermansia muciniphila Akk11 strain can be used to prepare products with the function of improving obesity.

[0084] The applicant declares that the technical solutions of the present application are illustrated by the above examples, but the present application is not limited to the above examples, i.e. it does not mean that the present application must rely on the above examples to be implemented. It should be understood by those skilled in the art that any improvement of the present application, equivalent replacement of each raw material of the product of the present application, addition of auxiliary ingredients, selection of specific methods, etc. fall within the protection scope and disclosure scope of the present application.

[0085] The preferred embodiments of the present application are described in detail above, but the present application is not limited to the specific details of the above-described embodiments, and various simple modifications can be made to the technical solutions of the present application within the technical concept of the present application, and these simple modifications all belong to the protection scope of the present application.

[0086] In addition, it should be noted that each specific technical feature described in the above specific embodiments can be combined in any appropriate manner without contradiction, and in order to avoid unnecessary repetition, various possible combinations are not described again in the present application.

Claims

1. Akkermansia muciniphila Akk11 with the function of regulating blood glucose and blood lipid, which is classified as Akkermansia muciniphila Akk11, has the accession number CCTCC NO: M 2024119, and was deposited on January 15, 2024.

2. A culture of Akkermansia muciniphila Akk11 with the function of regulating blood glucose and blood lipid according to claim 1, which is prepared by inoculating Akkermansia muciniphila Akk11 into a culture medium and culturing at 35-38°C for 18-22h.

3. A probiotic agent with the function of regulating blood glucose and blood lipid, wherein the strain comprises the Akkermansia muciniphila Akk11 strain according to claim 1.

4. The probiotic agent having the effect of regulating blood sugar and blood lipid according to claim 3, wherein, In the probiotic agent, the viable count of the mucinophilic Akkermansia Akk11 strain is not less than 1 x 10 10 CFU / mL or 1 x 10 10 CFU / g.

5. The probiotic agent having the effect of regulating blood sugar and blood lipid according to claim 3, wherein, The strain in the probiotic agent with the function of regulating blood glucose and blood lipid further comprises Bifidobacterium longum BL21, which is classified as Bifidobacterium longum, has the accession number CGMCC No. 10452, and was deposited on January 27, 2015.

6. The probiotic agent having the effect of regulating blood sugar and blood lipid according to claim 5, wherein, The ratio of viable bacterial counts of the Akkermansia muciniphila Akk11 strain and the Bifidobacterium longum BL21 strain is (1-10):(1-10).

7. The probiotic agent having the function of regulating blood sugar and blood lipid according to claim 3, wherein, The dosage form of the probiotic agent comprises a freeze-dried powder, a capsule, a tablet, or a granule.

8. The probiotic agent having the function of regulating blood sugar and blood lipid according to claim 3, wherein, The probiotic agent further comprises a protective agent and / or a functional aid; The protective agent comprises any one or a combination of at least two of skimmed milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol, or xylitol; The functional aid comprises any one or a combination of at least two of maltodextrin, fructooligosaccharide, galactooligosaccharide, xylooligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, grifola frondosa polysaccharide, stachyose, polydextrose, α-lactalbumin, or lactoferrin.

9. Use of the Akkermansia muciniphila Akk11 with the function of regulating blood glucose and blood lipid according to claim 1, the culture according to claim 2, or the probiotic agent according to any one of claims 3-8 in the preparation of a product with the function of preventing, improving, or treating obesity, hyperlipidemia, or hyperglycemia.

10. The use of claim 9, wherein, The product further comprises an excipient; The excipient comprises any one or a combination of at least two of a diluent, an excipient, a binder, a wetting agent, a disintegrant, an emulsifying agent, a solubilizing agent, a permeability regulator, a coating material, a coloring agent, a pH regulator, or a buffer. ​

Images